Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ZM-H1505R in Healthy Subjects
NCT04220801Phase 1Completed
- Sponsor
- Zhimeng Biopharma
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Canocapavir in Chronic Hepatitis B (CHB) (8 cohorts), sponsored by Zhimeng Biopharma. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events at 36 days, Number of Participants With Abnormal Physical Examinations at 36 days and 3 more. Started Feb 2020; status: completed.
02
Drugs
Canocapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04220801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220801.